Seres Therapeutics (MCRB) stock price, revenue, and financials

Seres Therapeutics market cap is $130.3 m, and annual revenue was $28.27 m in FY 2018

$130.3 M

MCRB Mkt cap, 10-Jun-2019

$1.8 M

Seres Therapeutics Revenue Q2, 2019
Seres Therapeutics Net income (Q2, 2019)-10.8 M
Seres Therapeutics EBIT (Q2, 2019)-10.9 M
Seres Therapeutics Cash, 30-Jun-2019102.2 M

Seres Therapeutics Income Statement

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018

Revenue

21.8m32.1m28.3m

R&D expense

38.1m82.0m89.5m96.0m

General and administrative expense

16.8m32.6m34.0m32.6m

Operating expense total

54.9m114.6m123.5m128.6m

EBIT

(54.9m)(92.8m)(91.4m)(100.3m)

EBIT margin, %

(427%)(285%)(355%)

Interest expense

555.0k969.0k1.6m1.2m

Interest income

638.0k2.2m1.6m1.2m

Net Income

(54.8m)(91.6m)(89.4m)(98.9m)

Quarterly

USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q1, 2019Q2, 2019

Revenue

2.7m3.0m13.0m3.0m3.0m23.0m4.0m4.6m260.0k1.8m

R&D expense

8.8m9.9m15.4m22.2m24.1m20.1m23.1m22.2m23.5m24.1m22.9m17.9m

General and administrative expense

3.6m4.7m7.2m9.0m8.0m8.8m8.4m8.1m8.8m8.7m7.5m5.6m

Operating expense total

12.3m14.6m22.6m31.1m32.1m28.9m31.4m30.3m32.2m32.7m31.9m23.5m

EBIT

(12.3m)(14.6m)(19.9m)(28.1m)(19.1m)(25.9m)(28.4m)(7.3m)(28.3m)(28.1m)(24.6m)(10.9m)

EBIT margin, %

(735%)(937%)(147%)(859%)(943%)(32%)(712%)(610%)(9443%)(603%)

Interest expense

5.0k59.0k56.0k268.0k312.0k347.0k220.0k189.0k

Interest income

5.0k59.0k268.0k495.0k719.0k775.0k615.0k502.0k347.0k349.0k220.0k189.0k

Net Income

(12.6m)(14.6m)(19.7m)(27.9m)(18.7m)(25.5m)(28.0m)(6.9m)(27.9m)(27.8m)(24.3m)(10.8m)

Seres Therapeutics Balance Sheet

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018

Cash

73.9m54.5m36.1m85.8m

Inventories

2.5m5.1m

Current Assets

207.6m198.4m155.1m92.7m

PP&E

7.8m36.1m32.9m26.3m

Total Assets

216.9m272.6m189.5m120.5m

Accounts Payable

5.4m7.6m7.0m6.4m

Current Liabilities

10.9m30.5m31.6m42.0m

Long-term debt

1.3m

Total Liabilities

140.0m128.8m168.5m

Additional Paid-in Capital

287.9m306.9m324.4m341.3m

Retained Earnings

(82.6m)(174.2m)(263.6m)(389.4m)

Total Equity

205.4m132.6m60.7m(48.0m)

Financial Leverage

1.1 x2.1 x3.1 x-2.5 x

Quarterly

USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q1, 2019Q2, 2019

Cash

36.3m69.7m193.2m59.8m55.6m41.9m33.6m46.0m47.2m58.0m53.6m102.2m

Accounts Receivable

6.7m1.6m

Current Assets

94.1m222.4m306.8m217.1m208.4m192.3m176.1m176.6m126.5m101.5m67.8m109.0m

PP&E

3.3m4.5m16.1m27.0m34.6m36.1m34.8m33.7m31.5m29.9m24.6m22.9m

Total Assets

101.3m227.0m324.5m306.2m297.5m244.9m216.3m211.9m159.4m133.0m107.0m146.1m

Accounts Payable

1.7m2.1m5.8m4.5m4.2m5.6m3.9m5.4m5.4m5.2m3.9m4.8m

Short-term debt

1.2m

Current Liabilities

5.6m4.8m24.8m27.3m31.9m27.2m25.7m27.0m35.2m36.8m41.6m43.1m

Long-term debt

727.0k1.3m

Total Debt

727.0k1.3m

Total Liabilities

6.4m4.8m134.6m138.8m143.5m133.4m128.4m126.4m149.4m146.2m176.9m164.1m

Additional Paid-in Capital

143.2m285.1m292.0m297.5m302.9m311.2m315.7m320.2m328.4m332.9m343.8m406.4m

Retained Earnings

(48.4m)(63.0m)(102.3m)(130.2m)(148.9m)(199.7m)(227.7m)(234.6m)(318.3m)(346.1m)(413.7m)(424.5m)

Total Equity

94.9m222.2m189.8m167.4m154.0m111.5m87.9m85.5m10.0m(69.8m)(18.0m)

Debt to Equity Ratio

0 x0 x

Debt to Assets Ratio

0 x0 x

Financial Leverage

1.1 x1 x1.7 x1.8 x1.9 x2.2 x2.5 x2.5 x15.9 x-1.5 x-8.1 x

Seres Therapeutics Cash Flow

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(54.8m)(91.6m)(89.4m)(98.9m)

Depreciation and Amortization

728.0k4.2m7.3m7.9m

Inventories

(2.5m)(2.6m)

Accounts Payable

2.7m3.6m(856.0k)(353.0k)

Cash From Operating Activities

(40.8m)43.9m(75.5m)(62.9m)

Purchases of PP&E

(4.4m)(21.5m)(4.7m)(1.9m)

Cash From Investing Activities

(137.1m)(65.5m)57.0m112.3m

Cash From Financing Activities

137.7m2.1m83.0k268.0k

Interest Paid

163.0k109.0k1.0k

Quarterly

USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q1, 2019Q2, 2019

Net Income

(20.5m)(35.1m)(19.7m)(27.9m)(66.3m)(25.5m)(53.5m)(60.4m)(27.9m)(55.7m)(24.3m)(35.1m)

Depreciation and Amortization

212.0k394.0k2.5m3.5m5.4m1.9m3.9m2.0m3.9m

Accounts Receivable

(6.7m)(1.6m)

Accounts Payable

(141.0k)532.0k5.8m4.5m84.0k5.6m(3.7m)(2.5m)(1.4m)(1.5m)(2.5m)(1.6m)

Cash From Operating Activities

(18.0m)(29.3m)64.7m(51.3m)(54.9m)(26.8m)

Purchases of PP&E

(1.6m)(3.1m)(15.8m)(3.5m)(4.0m)(953.0k)(1.7m)(306.0k)(647.0k)

Cash From Investing Activities

(57.2m)(152.9m)(85.2m)30.4m46.3m38.0m74.4m(306.0k)(647.0k)

Long-term Borrowings

(600.0k)(2.6m)

Cash From Financing Activities

(2.7m)137.7m2.1m36.0k108.0k(165.0k)(75.0k)480.0k61.2m

Interest Paid

75.0k162.0k109.0k1.0k

Seres Therapeutics Ratios

USDY, 2019

Financial Leverage

-8.1 x

Seres Therapeutics Employee Rating

3.815 votes
Culture & Values
3.6
Work/Life Balance
3.7
Senior Management
3.0
Salary & Benefits
3.5
Career Opportunities
3.4
Source